Abstract:ABSTRACT Tumor microenvironment (TME) contains a variety of infiltrating immune cells. Among them, tumor-associated macrophages (TAMs) and their alternative activation contribute greatly to the progression of tumors. The mechanisms governing macrophage polarization in the TME are unclear. Here, we show that in TAMs or macrophages under tumor-conditioned medium treatment, the expression of transcription factor EB (TFEB) is reduced and more of the TFEB protein is in an inactive cytosolic form. Transforming growth factor (TGF)-β is identified as a main driving force for the reduced TFEB expression and activity in TAMs via activating ERK signaling. TFEB interference in macrophages significantly enhanced their alternative activation, with reduced expression of MHC-II and co-stimulatory molecule CD80, decreased ability to activate T cells, and increased ability to attract tumor cells. When co-inoculated with tumor cells, macrophages with TFEB knockdown significantly enhanced tumor growth with increased infiltration of M2-like macrophages, reduced infiltration of CD8+ T cells, and enhanced angiogenesis in the tumors. Mechanistic studies revealed that TFEB downregulation resulted in macrophage M2 polarization through reducing SOCS3 production and enhancing STAT3 activation. We further demonstrate that the activation of TFEB by hydroxypropyl-β-cyclodextrin in macrophages suppressed their M2 polarization and tumor-promoting capacity, and that macrophage-specific TFEB overexpression inhibited breast tumor growth in mice. Therefore, our data suggest that TFEB plays critical roles in macrophage polarization, and the downregulation of TFEB expression and activation is an integral part of tumor-induced immune editing in the TME. This study provides a rationale for a new cancer treatment strategy by modulating macrophage polarization through activating TFEB.

Data from Phosphoinositide-Binding Protein TIPE1 Promotes Alternative Activation of Macrophages and Tumor Progression via PIP3/Akt/TGFβ Axis

Phosphoinositide-Binding Protein TIPE1 Promotes Alternative Activation of Macrophages and Tumor Progression Via PIP3/Akt/TGFβ Axis

Supplementary Data from Phosphoinositide-Binding Protein TIPE1 Promotes Alternative Activation of Macrophages and Tumor Progression via PIP3/Akt/TGFβ Axis

Supplementary Figure from Phosphoinositide-Binding Protein TIPE1 Promotes Alternative Activation of Macrophages and Tumor Progression Via PIP3/Akt/TGFβ Axis

TIPE2 Governs Macrophage Polarization Via Negative Regulation of Mtorc1

Regulation of inflammation and tumorigenesis by the TIPE family of phospholipid transfer proteins

TIPE3 is the Transfer Protein of Lipid Second Messengers That Promote Cancer.

TIPE drives a cancer stem-like phenotype by promoting glycolysis via PKM2/HIF-1alpha axis in melanoma

TIPE2 Negatively Regulates Mycoplasma Pneumonia-Triggered Immune Response Via MAPK Signaling Pathway

TIPE3 Protein Promotes Breast Cancer Metastasis Through Activating AKT and NF-κB Signaling Pathways

TIPE2 Suppresses Malignancy of Pancreatic Cancer Through Inhibiting TGFβ1 Mediated Signaling Pathway

Tumor Necrosis Factor--Induced Protein 8-Like 2 Negatively Regulates Innate Immunity Against RNA Virus by Targeting RIG-I in Macrophages

Abstract B08: Tumor-initiating Cell Associated Macrophages Play an Essential Role in Tumorigenesis

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Tumor Necrosis Factor α-Induced Protein 8-Like 1 Binds to Protein Arginine Methyltransferase 1 to Suppress the Methylation of Signal Transducer and Activator of Transcription 3 and Cell Growth in Oral Squamous Cell Carcinoma

Tumor Necrosis Factor (Tnf)-Α-induced Protein 8-Like-2 (TIPE2) Inhibits Proliferation and Tumorigenesis in Breast Cancer Cells.

TIPE1 Induces Apoptosis by Negatively Regulating Rac1 Activation in Hepatocellular Carcinoma Cells

Timp1 Promotes Cell Survival by Activating the PDK1 Signaling Pathway in Melanoma

Transcriptional factor EB regulates macrophage polarization in the tumor microenvironment

The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras.